---
schema_version: "secwatch.filing_event.v1"
accession: "0001867096-23-000121"
form_type: "8-K"
ticker: "XERS"
cik: "0001867096"
company_name: "Xeris Biopharma Holdings, Inc."
filed_at: "2023-09-27T23:59:59+00:00"
generated_at: "2026-06-10T08:21:52.285244+00:00"
event_type: "debt"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Xeris exchanges $32M of 5% 2025 notes for $33.6M of 8% 2028 notes; extends debt maturity

## Summary
- Exchanged $31,975,000 of 5% convertible notes due 2025 for $33,574,000 of 8% notes due July 2028.
- Conversion price unchanged at ~$3.06 per share (~68% premium to Sept 26 closing price).
- Only ~$15.2M of original 2025 notes remain; no other debt due until 2027.
- Notes are senior unsecured; interest payable semi-annually starting Jan 15, 2024.
- Redeemable after July 20, 2026 if stock exceeds 130% of conversion price.

## SEC filing metadata
- accession: 0001867096-23-000121
- form_type: 8-K
- ticker: XERS
- cik: 0001867096
- company_name: Xeris Biopharma Holdings, Inc.
- filed_at: 2023-09-27T23:59:59+00:00
- event_type: debt
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1867096/000186709623000121/0001867096-23-000121-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1867096/000186709623000121/xers-20230926.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001867096-23-000121
- JSON: https://secwatch.observer/filing/0001867096-23-000121.json
- Plain text: https://secwatch.observer/filing/0001867096-23-000121.txt

## Key facts
- Material Agreements
  Xeris Biopharma Holdings, Inc. entered into Exchange Agreements with certain holders of the Guarantor's outstanding 5.00% Convertible Senior Notes due 2025 valued at $31,975,000 in aggregate principal amount of the Existing Notes for $33,574,000 in aggregate princip (effective 2023-09-26).
  - Action: entry
  - Agreement: notes offering
  - Counterparty: certain holders of the Guarantor's outstanding 5.00% Convertible Senior Notes due 2025
  - Value: $31,975,000 in aggregate principal amount of the Existing Notes for $33,574,000 in aggregate princip
  - Effective: 2023-09-26
  source text: On September 26, 2023, Xeris Biopharma Holdings, Inc., a Delaware corporation (the “ Company ”), and Xeris Pharmaceuticals, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (the “ Guarantor ”), entered into separate, privately negotiated exchange agreements (the “ Exchange Agreements ”) with certain holders of the Guarantor’s outstanding 5.00% Convertible Senior Notes due 2025 (the “ Existing Notes ”), pursuant to which the Company will exchange $31,975,000 in aggregate principal amount of the Existing Notes for $33,574,000 in aggregate principal amount of the Company’s new 8.00% Convertible Senior Notes due 2028 (the “ New Notes ”) (the “ Exchange Transactions ”), in each case, pursuant to the exemption from registration provided by Section 4(a)(2) under the Securities Act of 1933, as amended (the “ Securities Act ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1867096/000186709623000121/0001867096-23-000121-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.